Interaction study between antiplatelet agents, anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (Meriva ®).

CONCLUSIONS: Results from this non-interaction clinical study suggest that Meriva® does not interfere with the antiplatelet activity of the most common antiplatelet agents nor alters the INR values in stable patients assuming warfarin or dabigatran. Similarly, dosages of LT4 or metformin do not need to be adjusted in case of complementary treatment with Meriva®.
PMID: 30070343 [PubMed - in process]

Source: Pharmacological Reviews - August 1, 2018 Category: Drugs & Pharmacology Authors: Hu S, Belcaro G, Dugall M, Peterzan P, Hosoi M, Ledda A, Riva A, Giacomelli L, Togni S, Eggenhoffner R, Cotellese R Tags: Eur Rev Med Pharmacol Sci Source Type: research